GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Serina Therapeutics SER · USD

Health Care · US listing · 🇺🇸 United States

Compare

1.43

+3.62%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2023

Revenue

$142,000

FY2016FY2023

Net income

−$14.8m

FY2016FY2023

Free cash flow

−$7.8m

FY2016FY2023

Shareholders' equity

$5.5m

FY2016FY2023

Income statement

Fiscal years

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$142,000$30,000$140,000$360,000$1.7m$1.4m$1.4m$1.7m
Gross profit$102,000$20,000$130,000$340,000$1.5m$1.0m$1.2m$1.4m
Research and development$603,000$890,000$1.3m$3.6m$5.9m$6.6m$5.8m$8.5m
Operating income−$10.0m−$7.0m−$8.0m−$10.1m−$12.6m−$11.3m−$8.4m−$12.7m
Net income−$14.8m−$10.5m−$8.7m−$10.9m−$12.2m−$7.5m−$6.6m−$15.5m
Diluted earnings per share-13.72-0.28-0.23-0.27-0.33-0.21-0.18-0.43

Balance sheet

At each fiscal year end

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$12.0m$3.2m$3.1m$3.9m$7.4m$10.7m$9.6m$3.2m
Cash and short-term investments$345,000$650,000$580,000$530,000$2.4m$6.7m$7.4m$260,000
Total liabilities$6.5m$20.4m$15.0m$9.0m$5.2m$3.2m$2.4m$26.6m
Debt$4.4m$18.1m$13.2m$6.3m$1.5m———
Shareholders' equity$5.5m−$17.2m−$11.8m−$5.1m$2.2m$7.5m$7.3m−$23.4m
Shares outstanding1m38m38m38m37m35m36m36m

Cash flow

Fiscal years

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$7.8m−$5.9m−$7.9m−$7.8m−$10.2m−$8.0m−$6.3m−$8.4m
Capital spending———−$20,000−$640,000−$1.9m—−$20,000
Free cash flow−$7.8m−$5.9m−$7.9m−$7.8m−$10.8m−$9.9m−$6.3m−$8.4m

Latest quarters

By quarter end

Jun 2025Mar 2025Sept 2024Jun 2024Mar 2024Dec 2023Sept 2023Jun 2023
Revenue$130,000—$14,000$51,000$5,000$56,000$70,000$10,000
Gross profit—————$55,000$30,000—
Operating income−$5.6m−$5.9m−$5.3m−$3.9m−$2.3m−$3.6m−$2.4m−$1.9m
Net income−$6.4m−$4.8m$1.4m$5.2m−$15.0m−$3.5m−$5.4m−$2.7m
Diluted earnings per share-0.64-0.490.130.61-2.12-3.20-0.14-0.07
Total assets$8.9m$6.7m$7.4m$10.7m$10.9m$12.0m$12.2m$12.3m
Cash and short-term investments$6.0m$4.3m$3.2m$6.1m$8.7m$345,000$400,000$260,000
Debt——$693,000$693,000$693,000$693,000$690,000$10.1m
Shareholders' equity$1.8m$1.7m−$13.8m−$16.4m−$4.3m$5.5m$8.4m−$22.2m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-26.3%-49.6%—
Operating income28.5%6.3%—
Net income8.7%-1.7%—

Valuation history

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Price to earnings-3.3-1.0-71.5-169.9-188.1-199.4-497.1
Price to sales—104.5—————

Share price return

Finished calendar years

20252024202320222021202020192018
Return-57%-54%-36%9%-67%5%-38%-8%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 35.17-to-1 reverse split · 15 Mar 2024

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.